Archive · 16 Sep 2025
Pharma Stocks Decline Amid US Headwinds, Despite Domestic Growth
Imagine that Indian drug companies are like stores selling medicine.
Their stock prices have dropped this year, even though the overall market is doing okay.
This is because the US, which buys a lot of their products, is making it harder for them to sell.
The US is worried about how much they charge for these medicines and is also making sure that the medicines are safe and meet quality standards.
This is hurting the companies' profits.
However, the medicine market in India is doing well.
Some companies are doing better by focusing on selling medicines inside India.
Analysts suggest investors should be cautious and selective when deciding which stocks to invest in.
Indian pharma stocks have declined due to concerns over the US market.
The Nifty Pharma index has fallen 5.18% YTD, while the Nifty 50 gained 6.02%.
Export realisations and potential tariffs are pressuring the sector.
The Indian pharma market grew 8.7% in August, driven by domestic demand.
Analysts recommend cautious, selective investment strategies.
- Who
- Indian pharma companies
- What
- Experiencing decline in stock value due to US market headwinds and domestic market growth
- When
- Year-to-date as of September 15th
- Where
- US and Indian markets
- Why
- Weakening demand, pricing pressures and regulatory scrutiny in the US
- Nifty Pharma Index YTD Decline
- 5.18%
- Nifty 50 YTD Gain
- 6.02%
- August India Pharma Market Growth
- 8.7%
- Sun Pharma's Domestic Growth
- 13.7%
- Torrent's Domestic Growth
- 13.5%